Onivyde(Irinotecan Liposomal)
IPN.PA
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Ipsen S.a.
$2.2M
Medicare cost, 2024
$2.2M
Medicare cost, 2024
Medicare drug plans spent $2.2 million on Onivyde (irinotecan liposomal) in 2024, for 167 prescriptions and refills filled by 47 patients. Spending rose 64% from 2023 to 2024. At about $13,376 per prescription it is a high-cost drug. New York accounts for the most spending ($622,067, 28% of the total).
Medicare cost, 2024
$2.2M
+64.4% from 2023
Prescriptions
167
$13,375.66 per claim
Patients
47
38 prescribers
Total spending, 2024
$2.2M
$47,526.30 per patient
Questions and answers
How much does Medicare spend on Onivyde?
Medicare prescription drug plans paid $2.2M for Onivyde in 2024, for 167 prescriptions and refills to 47 patients (up 64.4% from 2023). The average cost per claim was $13,375.66.
Which state spends the most on Onivyde?
New York had the highest Medicare cost for Onivyde in 2024: $622K for 40 claims, followed by Florida ($429K).
Who prescribes Onivyde the most?
M Ashraf Meelu, hematology-oncology in Waldorf, MD, had the highest Medicare cost for Onivyde in 2024: 14 claims costing $283K.
Who makes Onivyde?
Onivyde is made by Ipsen S.a. (IPN.PA), listed in the Medicare spending data as Ipsen Biopharma.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Onivyde was $2.2M in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Onivyde, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| M Ashraf Meelu Waldorf, MD | Hematology-Oncology | 14 | Under 11 | $283K |
| Zili He X Flushing, NY | Hematology-Oncology | 12 | Under 11 | $193K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 17 | 64 | 19 | $758K |
| 2023 | 22 | 98 | 24 | $1.4M |
| 2024 | 38 | 167 | 47 | $2.2M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Ipsen Biopharma | 167 | $2.2M |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.